Description de l'entreprise
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in clinical development for multiple myeloma and non-Hodgkin's lymphoma, in addition to other clinical programs, and an innovative pre-clinical pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.
Conseil d'administration & Conseil de surveillance
| PDG |
| Prof. Dr. Jan G. J. van de Winkel |
| Conseil d'administration |
| Anthony Pagano, Birgitte Stephensen, Christopher Cozic, Dr. Martine J. van Vugt, Judith Klimovsky, M.D., Tahamtan Ahmadi, Rayne Waller, Brad Bailey |
| Conseil de surveillance |
| Deirdre P. Connelly, Pernille Erenbjerg, Dr. Anders Gersel Pedersen, Paolo Paoletti, M.D., Rolf Hoffmann, Elizabeth O’Farrell, Martin Schultz, Takahiro Hamatani, Mijke Zachariasse |
Données de l'entreprise
| Nom: |
Genmab A/S |
| Adresse: |
Kalvebod Brygge 43,DK-1560 Copenhagen |
| Téléphone: |
+45-7020-2728 |
| Fax: |
+45-7020-2729 |
| Courriel: |
info@genmab.com
|
| Internet: |
www.genmab.com |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
- |
| IPO date: |
18/10/2000 |
Relations avec les investisseurs
| Nom: |
Andrew Carlsen |
| Téléphone IR: |
+45-3377-9558 |
| IR-Fax: |
- |
| E-mail IR: |
ir@genmab.com
|
